These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37041636)

  • 1. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
    Wu X; Jiao Z; Zhang J; Li F; Li Y
    J Nanobiotechnology; 2023 Apr; 21(1):126. PubMed ID: 37041636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
    Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
    Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
    Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
    Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
    Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
    Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
    Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
    PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
    Yin B; Kogan SC; Dickins RA; Lowe SW; Largaespada DA
    Exp Hematol; 2006 May; 34(5):631-41. PubMed ID: 16647569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
    Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
    Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.
    Yuan F; Cheng C; Xiao F; Liu H; Cao S; Zhou G
    Life Sci; 2020 Feb; 243():117276. PubMed ID: 31926250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
    Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
    J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
    Chen L; Hu N; Wang C; Zhao H
    Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
    Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
    Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dose and schedule of consolidation in AML: is there a standard?
    Schiffer CA
    Best Pract Res Clin Haematol; 2014; 27(3-4):259-64. PubMed ID: 25455275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Liu J; Luo W; Chen Q; Chen X; Zhou G; Sun H
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):243-253. PubMed ID: 35066694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.